CARMUSTINE Side Effects

6710162-9 | Brain Abscess, Sepsis
on Apr 26, 2010 Male patient from FRANCE , 57 years of age, was diagnosed with glioblastoma and was treated with Carmustine (View Usage). Patient experienced the following unwanted or unexpected effects: brain abscess, sepsis (What is sepsis?). Carmustine dosage: Six Implants. Patient was hospitalized.

6248169-0 | Carbon Monoxide Diffusing Capacity Decreased, Dyspnoea Exertional, Haemoglobin Decreased, Leukopenia, Neutropenia, Pulmonary Toxicity, Thrombocytopenia
Patient was taking Carmustine (View Usage). Patient had the following side effects: carbon monoxide diffusing capacity decreased, dyspnoea exertional, haemoglobin decreased, leukopenia, neutropenia, pulmonary toxicity, thrombocytopenia on Jun 24, 2009 from UNITED STATES Additional patient health information: Female patient , 72 years of age, weighting 142.4 lb, was diagnosed with astrocytoma and. Carmustine dosage: 134mg Per Day X 3 Iv Drip.

6115318-4 | Pulmonary Fibrosis
Adverse event was reported on Sep 07, 2008 by a Male patient taking Carmustine (View Usage) (Dosage: ) was diagnosed with glioblastoma multiforme and. Location: UNITED STATES , 51 years of age, After Carmustine was administered, patient had the following side effects: pulmonary fibrosis (What is pulmonary fibrosis?). During the same period patient was treated with DILANTIN (View Dilantin Review and Dilantin Label ), KEPPRA (View Keppra Review and Keppra Label ), ZONEGRAN (View Zonegran Review and Zonegran Label ), DECADRON (View Decadron Review and Decadron Label ), ACTONEL (View Actonel Review and Actonel Label ), PREDNISONE (View Prednisone Review and Prednisone Label ), LEXAPRO (View Lexapro Review and Lexapro Label ).

6024651-6 | Acute Graft Versus Host Disease, Obliterative Bronchiolitis, Respiratory Failure
on Dec 29, 2008 Female patient from UNITED KINGDOM , 60 years of age, weighting 174.2 lb, was diagnosed with stem cell transplant and was treated with Carmustine (View Usage). Patient experienced the following unwanted or unexpected effects: acute graft versus host disease, obliterative bronchiolitis, respiratory failure. Carmustine dosage: . During the same period patient was treated with FLUDARABINE PHOSPHATE (View Fludarabine Phosphate Review and Fludarabine Phosphate Label ), MELPHALAN (View Melphalan Review and Melphalan Label ), CERTICAN (Formulation-tabs;reg#2 - (2.5g)22jul08;reg#3-(1g)23-31jul08(9days);reg#4-(0.5g)01aug08) (View Certican Review and Certican Label ), MYFORTIC (Formulation-tabs;reg#2 - (2.5g)22jul08;reg#3-(1g)23-31jul08(9days);reg#4-(0.5g)01aug08) (View Myfortic Review and Myfortic Label ). Patient was hospitalized and became disabled.


5908610-7 | Brain Natriuretic Peptide Increased, Cardiac Failure Congestive, Ejection Fraction Decreased, Platelet Count Decreased, Pleural Effusion, Ventricular Dysfunction, Weight Increased
on Sep 15, 2008 Female patient from UNITED STATES , 58 years of age, weighting 149.9 lb, was diagnosed with diffuse large b-cell lymphoma and was treated with Carmustine (View Usage). Patient had the following side effects: brain natriuretic peptide increased, cardiac failure congestive, ejection fraction decreased, platelet count decreased, pleural effusion, ventricular dysfunction, weight increased. Carmustine dosage: 225 Mg; Daily; Intravenous. During the same period patient was treated with CYCLOPHOSPHAMIDE (2.295 Gm; Daily; Intravenous) (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE (930 Mg;daily;intravenous) (View Etoposide Review and Etoposide Label ), DOXORUBICIN HCL (View Doxorubicin Hcl Review and Doxorubicin Hcl Label ), VINCRISTINE (View Vincristine Review and Vincristine Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ). Patient was hospitalized.

5760681-7 | Convulsion
Patient was taking Carmustine (View Usage). After Carmustine was administered, patient had the following side effects: convulsion on Jun 03, 2008 from UNITED STATES Additional patient health information: Male patient , 61 years of age, weighting 194.0 lb, was diagnosed with glioblastoma multiforme and. Carmustine dosage: . During the same period patient was treated with RITALIN (View Ritalin Review and Ritalin Label ), THALIDOMIDE (View Thalidomide Review and Thalidomide Label ), IRINOTECAN HCL (125 Mg/m2 Iv Over 90min,day 1 + 15. First Course On 11-oct-2007.) (View Irinotecan Hcl Review and Irinotecan Hcl Label ), BEVACIZUMAB (10 Mg/kg Iv Over 90-30min Days 1-15. First Course On 11-oct-2007.) (View Bevacizumab Review and Bevacizumab Label ). Patient was hospitalized.

5754966-8 | Blood Pressure Decreased, Fatigue, Lung Infiltration, Pneumonitis, Refusal Of Treatment By Patient
Adverse event was reported on May 28, 2008 by a Male patient taking Carmustine (View Usage) (Dosage: 990 Mg) . Location: UNITED STATES , weighting 188.1 lb, Patient experienced the following unwanted or unexpected effects: blood pressure decreased, fatigue, lung infiltration, pneumonitis, refusal of treatment by patient. During the same period patient was treated with CYCLOPHOSPHAMIDE (6920 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE (4152 Mg) (View Etoposide Review and Etoposide Label ), RITUXIMAB (MOAB C2B8 ANTI CD20, CHIMERIC) (730 Mg) (View Rituximab (moab C2b8 Anti Cd20, Chimeric) Review and Rituximab (moab C2b8 Anti Cd20, Chimeric) Label ). Patient was hospitalized.

5730201-1 | Atelectasis, Interstitial Lung Disease, Pneumonia, Pneumonitis
on May 05, 2008 Male patient from UNITED STATES , weighting 188.1 lb, was treated with Carmustine (View Usage). Patient had the following side effects: atelectasis, interstitial lung disease, pneumonia (What is pneumonia?), pneumonitis. Carmustine dosage: 990 Mg. During the same period patient was treated with CYCLOPHOSPHAMIDE (6920 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE (4152 Mg) (View Etoposide Review and Etoposide Label ), RITUXIMAB (MOAB C2B8 ANTI CD20, CHIMERIC) (730 Mg) (View Rituximab (moab C2b8 Anti Cd20, Chimeric) Review and Rituximab (moab C2b8 Anti Cd20, Chimeric) Label ). Patient was hospitalized.

5707442-2 | Acute Myocardial Infarction, Acute Respiratory Distress Syndrome, Pneumocystis Jiroveci Pneumonia, Pneumonia Cytomegaloviral, Renal Failure
on Apr 11, 2008 Male patient from UNITED STATES , 77 years of age, was treated with Carmustine (View Usage). After Carmustine was administered, patient had the following side effects: acute myocardial infarction, acute respiratory distress syndrome, pneumocystis jiroveci pneumonia, pneumonia cytomegaloviral, renal failure. Carmustine dosage: . During the same period patient was treated with DEXAMETHASONE TAB (View Dexamethasone Tab Review and Dexamethasone Tab Label ). Patient was hospitalized.

5679974-7 | Inflammation, Pleural Effusion, Pneumonia
Patient was taking Carmustine (View Usage). Patient experienced the following unwanted or unexpected effects: inflammation, pleural effusion, pneumonia (What is pneumonia?) on Mar 25, 2008 from UNITED STATES Additional patient health information: Male patient , weighting 189.6 lb, . Carmustine dosage: 990 Mg. During the same period patient was treated with CYCLOPHOSPHAMIDE (6920 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE (4152 Mg) (View Etoposide Review and Etoposide Label ), RITUXIMAB (MOAB C2B8 ANTI CD20, CHIMERIC) (730 Mg) (View Rituximab (moab C2b8 Anti Cd20, Chimeric) Review and Rituximab (moab C2b8 Anti Cd20, Chimeric) Label ). Patient was hospitalized.

5660861-5 | Myelodysplastic Syndrome
Adverse event was reported on Dec 04, 2007 by a Male patient taking Carmustine (View Usage) (Dosage: ) was diagnosed with astrocytoma and. Location: UNITED STATES , 42 years of age, Patient had the following side effects: myelodysplastic syndrome.

5660860-3 | Pulmonary Fibrosis
on Jul 31, 2007 Male patient from UNITED STATES , 51 years of age, was diagnosed with glioblastoma multiforme and was treated with Carmustine (View Usage). After Carmustine was administered, patient had the following side effects: pulmonary fibrosis (What is pulmonary fibrosis?). Carmustine dosage: . During the same period patient was treated with DILANTIN (View Dilantin Review and Dilantin Label ), KEPPRA (View Keppra Review and Keppra Label ), ZONEGRAN (View Zonegran Review and Zonegran Label ), DECADRON (View Decadron Review and Decadron Label ), ACTONEL (View Actonel Review and Actonel Label ), PREDNISONE TAB (View Prednisone Tab Review and Prednisone Tab Label ), LEXAPRO (View Lexapro Review and Lexapro Label ).

5593103-X | Abdominal Discomfort, Anorexia, Aspiration, Asthenia, Bronchoalveolar Lavage Abnormal, Headache, International Normalised Ratio Increased, Lung Infiltration, Metabolic Acidosis
on Jan 14, 2008 Female patient from UNITED STATES , weighting 136.5 lb, was treated with Carmustine (View Usage). Patient experienced the following unwanted or unexpected effects: abdominal discomfort, anorexia, aspiration, asthenia, bronchoalveolar lavage abnormal, headache (What is headache?), international normalised ratio increased, lung infiltration, metabolic acidosis. Carmustine dosage: 794 Mg. During the same period patient was treated with CYCLOPHOSPHAMIDE (5290 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE (3174 Mg) (View Etoposide Review and Etoposide Label ), MESNA (6348 Mg) (View Mesna Review and Mesna Label ), RITUXIMAB (MOAB C2B8 ANTI CD20, CHIMERIC) (1186 Mg) (View Rituximab (moab C2b8 Anti Cd20, Chimeric) Review and Rituximab (moab C2b8 Anti Cd20, Chimeric) Label ). Patient was hospitalized.

5485372-1 | Herpes Zoster
Patient was taking Carmustine (View Usage). Patient had the following side effects: herpes zoster on Oct 08, 2007 from UNITED KINGDOM Additional patient health information: Female patient , 42 years of age, was diagnosed with t-cell chronic lymphocytic leukaemia and. Carmustine dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MELPHALAN (View Melphalan Review and Melphalan Label ), CAMPATH (View Campath Review and Campath Label ).

5458590-6 | Hypermetropia, Microphthalmos, Pregnancy
Adverse event was reported on Sep 17, 2007 by a Male patient taking Carmustine (View Usage) (Dosage: Day 1 Every Other Month.) . Location: HONG KONG , child 1 years of age, After Carmustine was administered, patient had the following side effects: hypermetropia, microphthalmos, pregnancy (What is pregnancy?). During the same period patient was treated with CISPLATIN (On Days 1-3) (View Cisplatin Review and Cisplatin Label ), TAMOXIFEN CITRATE (View Tamoxifen Citrate Review and Tamoxifen Citrate Label ), DACARBAZINE (On Days 1-3) (View Dacarbazine Review and Dacarbazine Label ).

5430621-9 | Herpes Zoster
on Aug 27, 2007 Female patient from UNITED KINGDOM , 42 years of age, was diagnosed with t-cell chronic lymphocytic leukaemia and was treated with Carmustine (View Usage). Patient experienced the following unwanted or unexpected effects: herpes zoster. Carmustine dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MELPHALAN (View Melphalan Review and Melphalan Label ), CAMPATH (View Campath Review and Campath Label ).

5330056-3 | Anaemia Haemolytic Autoimmune, Autoimmune Thrombocytopenia, Coombs Direct Test Positive, Jaundice, Polychromasia, Reticulocytosis, Spherocytic Anaemia
on May 17, 2007 Female patient from UNITED KINGDOM , 41 years of age, was diagnosed with stem cell transplant, prophylaxis and was treated with Carmustine (View Usage). Patient had the following side effects: anaemia haemolytic autoimmune, autoimmune thrombocytopenia, coombs direct test positive, jaundice (What is jaundice?), polychromasia, reticulocytosis, spherocytic anaemia. Carmustine dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), MELPHALAN (View Melphalan Review and Melphalan Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MABCAMPATH (View Mabcampath Review and Mabcampath Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

5324033-6 | White Blood Cell Count Decreased
Patient was taking Carmustine (View Usage). After Carmustine was administered, patient had the following side effects: white blood cell count decreased on May 09, 2007 from UNITED STATES Additional patient health information: Male patient , 39 years of age, weighting 176.8 lb, was diagnosed with non-hodgkin's lymphoma and. Carmustine dosage: 288mg Daily For 3 Days Iv Drip. During the same period patient was treated with ETOPOSIDE (4488mg Once Iv Drip) (View Etoposide Review and Etoposide Label ), ATRIPLA (View Atripla Review and Atripla Label ), ATIVAN (View Ativan Review and Ativan Label ), AMBIEN (View Ambien Review and Ambien Label ), NEUPOGEN (View Neupogen Review and Neupogen Label ), GM CSF (View Gm-csf Review and Gm-csf Label ). Patient was hospitalized.

5227037-7 | Asthenia, Blood Ph Increased, Chest Discomfort, Dilatation Atrial, Dilatation Ventricular, Dyspnoea, Hypoxia, Low Cardiac Output Syndrome, Lung Neoplasm
Adverse event was reported on Feb 01, 2007 by a Female patient taking Carmustine (View Usage) (Dosage: 225 Mg) . Location: UNITED STATES , weighting 119.0 lb, Patient experienced the following unwanted or unexpected effects: asthenia, blood ph increased, chest discomfort, dilatation atrial, dilatation ventricular, dyspnoea, hypoxia, low cardiac output syndrome, lung neoplasm. During the same period patient was treated with CYCLOPHOSPHAMIDE (2004 Mg) (View Cyclophosphamide Review and Cyclophosphamide Label ), ETOPOSIDE (3096 Mg) (View Etoposide Review and Etoposide Label ). Patient was hospitalized.

5180974-4 | Haemoptysis, Respiratory Failure
on Dec 14, 2006 Female patient from UNITED STATES , weighting 176.4 lb, was diagnosed with metastatic malignant melanoma and was treated with Carmustine (View Usage). Patient had the following side effects: haemoptysis, respiratory failure. Carmustine dosage: 285 Mg X 5 Cycles Over 2 Hrs Iv. Patient was hospitalized.

4893424-X | Alanine Aminotransferase Increased, Aspartate Aminotransferase Increased, Blood Alkaline Phosphatase Increased, Headache, Thrombocytopenia, Vision Blurred
on Jan 25, 2006 Female patient from UNITED STATES , weighting 152.3 lb, was diagnosed with anaplastic astrocytoma and was treated with Carmustine (View Usage). After Carmustine was administered, patient had the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood alkaline phosphatase increased, headache (What is headache?), thrombocytopenia, vision blurred. Carmustine dosage: See Image. Patient was hospitalized.

4815552-7 | Abulia, Brain Abscess, Cerebral Infarction, Methicillin-resistant Staphylococcal Aureus Test Positive, Mutism
Patient was taking Carmustine (View Usage). Patient experienced the following unwanted or unexpected effects: abulia, brain abscess, cerebral infarction, methicillin-resistant staphylococcal aureus test positive, mutism on Oct 28, 2005 from UNITED STATES Additional patient health information: Female patient , weighting 157.1 lb, was diagnosed with anaplastic astrocytoma and. Carmustine dosage: See Image. During the same period patient was treated with RT (View Rt Review and Rt Label ). Patient was hospitalized.

4809827-5 | Abulia, Brain Abscess, Cerebral Infarction, Mutism, Staphylococcal Infection
Adverse event was reported on Oct 24, 2005 by a Female patient taking Carmustine (View Usage) (Dosage: See Image) was diagnosed with anaplastic astrocytoma and. Location: UNITED STATES , weighting 157.1 lb, Patient had the following side effects: abulia, brain abscess, cerebral infarction, mutism, staphylococcal infection (What is staphylococcal infection?). During the same period patient was treated with RADIATION RT (See Image) (View Radiation Rt Review and Radiation Rt Label ). Patient was hospitalized.

4736256-5 | Asthenia, Atrial Fibrillation, Blood Electrolytes Abnormal, Cardiac Failure, Clostridium Colitis, Culture Throat Positive, Cytomegalovirus Infection, Multi-organ Failure, Pneumonia
on Aug 05, 2005 Male patient from UNITED STATES , 71 years of age, weighting 178.6 lb, was treated with Carmustine (View Usage). After Carmustine was administered, patient had the following side effects: asthenia, atrial fibrillation (What is atrial fibrillation?), blood electrolytes abnormal, cardiac failure, clostridium colitis, culture throat positive, cytomegalovirus infection (What is cytomegalovirus infection?), multi-organ failure, pneumonia (What is pneumonia?). Carmustine dosage: 570mg Qdx1 Iv. During the same period patient was treated with ETOPOSIDE (380 Mg Qdx4 Iv) (View Etoposide Review and Etoposide Label ), CYTARABINE (570 Mg Qdx1 Iv) (View Cytarabine Review and Cytarabine Label ), MELPHALAN (380 Mg Qdx4 Iv) (View Melphalan Review and Melphalan Label ), ACYCLOVIR (View Acyclovir Review and Acyclovir Label ), DOXYCYCLINE (View Doxycycline Review and Doxycycline Label ), DIGOXIN (View Digoxin Review and Digoxin Label ), LOVENOX (View Lovenox Review and Lovenox Label ), PROTONIX (View Protonix Review and Protonix Label ).

4661709-8 | Acute Myocardial Infarction, Acute Respiratory Distress Syndrome, Pneumocystis Jiroveci Pneumonia, Pneumonia Cytomegaloviral, Renal Failure
on May 12, 2005 Male patient from , weighting 186.3 lb, was treated with Carmustine (View Usage). Patient experienced the following unwanted or unexpected effects: acute myocardial infarction, acute respiratory distress syndrome, pneumocystis jiroveci pneumonia, pneumonia cytomegaloviral, renal failure. Carmustine dosage: . During the same period patient was treated with DEXAMETHASONE (View Dexamethasone Review and Dexamethasone Label ).

4652118-6 | Cholelithiasis, Pancreatitis
Patient was taking Carmustine (View Usage). Patient had the following side effects: cholelithiasis, pancreatitis on May 02, 2005 from Additional patient health information: Female patient , weighting 179.5 lb, was diagnosed with anaplastic astrocytoma and. Carmustine dosage: 60 Mg/m2, Iv Days 1-3 Every Two Months (patient Was Dose Reduced After First Cycle To 60 Mg M2).

4630347-5 | Brain Oedema, Confusional State, Headache, Incontinence
Adverse event was reported on Apr 05, 2005 by a Male patient taking Carmustine (View Usage) (Dosage: 170mg,iv) was diagnosed with astrocytoma and. Location: , weighting 201.0 lb, After Carmustine was administered, patient had the following side effects: brain oedema, confusional state, headache (What is headache?), incontinence. During the same period patient was treated with RADIATION (View Radiation Review and Radiation Label ). Patient was hospitalized.

4623127-8 | Body Temperature Increased, Convulsion, Headache, Malignant Neoplasm Progression
on Mar 28, 2005 Female patient from , weighting 203.3 lb, was diagnosed with anaplastic astrocytoma and was treated with Carmustine (View Usage). Patient experienced the following unwanted or unexpected effects: body temperature increased, convulsion, headache (What is headache?), malignant neoplasm progression. Carmustine dosage: 209 Mg Iv Once Q 6 Weeks. During the same period patient was treated with TOPOTECAN 1.50 MG/M2/72 HR (3.14 Mg Iv Weekly Via 72hr Infusion) (View Topotecan 1.50 Mg/m2/72 Hr Review and Topotecan 1.50 Mg/m2/72 Hr Label ), COLACE (View Colace Review and Colace Label ), DILANTIN (View Dilantin Review and Dilantin Label ), DECADRON (View Decadron Review and Decadron Label ), PROTONIX (View Protonix Review and Protonix Label ), COUMIDIN (View Coumidin Review and Coumidin Label ). Patient was hospitalized.

4620626-X | Anaemia Haemolytic Autoimmune, Autoimmune Thrombocytopenia, Coombs Direct Test Positive, Jaundice, Polychromasia, Reticulocytosis, Spherocytic Anaemia
on Mar 23, 2005 Female patient from , 41 years of age, was diagnosed with prophylaxis and was treated with Carmustine (View Usage). Patient had the following side effects: anaemia haemolytic autoimmune, autoimmune thrombocytopenia, coombs direct test positive, jaundice (What is jaundice?), polychromasia, reticulocytosis, spherocytic anaemia. Carmustine dosage: . During the same period patient was treated with ETOPOSIDE (View Etoposide Review and Etoposide Label ), MELPHALAN (View Melphalan Review and Melphalan Label ), CYTARABINE (View Cytarabine Review and Cytarabine Label ), MABCAMPATH (View Mabcampath Review and Mabcampath Label ), CYCLOSPORINE (View Cyclosporine Review and Cyclosporine Label ), METHOTREXATE (View Methotrexate Review and Methotrexate Label ).

4619887-2 | Brain Oedema, Convulsion, Coordination Abnormal, Headache
Patient was taking Carmustine (View Usage). After Carmustine was administered, patient had the following side effects: brain oedema, convulsion, coordination abnormal, headache (What is headache?) on Mar 21, 2005 from Additional patient health information: Male patient , weighting 221.3 lb, was diagnosed with glioblastoma multiforme and. Carmustine dosage: 220mg Iv Once Q 6 Weeks. During the same period patient was treated with TOPOTECAN 1.5MG/M2/72HR (3.30mg Iv Over 72hrs Weekly X 6 Wks) (View Topotecan 1.5mg/m2/72hr Review and Topotecan 1.5mg/m2/72hr Label ), DILANTIN (View Dilantin Review and Dilantin Label ), RITALIN (View Ritalin Review and Ritalin Label ), AMBIEN (View Ambien Review and Ambien Label ). Patient was hospitalized.

4611393-4 | Cholelithiasis, Emphysematous Cholecystitis, Malignant Neoplasm Progression
Adverse event was reported on Mar 15, 2005 by a Male patient taking Carmustine (View Usage) (Dosage: 200mg Iv Once Q 6 Weeks) was diagnosed with glioblastoma multiforme and. Location: , weighting 172.8 lb, Patient experienced the following unwanted or unexpected effects: cholelithiasis, emphysematous cholecystitis, malignant neoplasm progression. During the same period patient was treated with TOPOTECAN 1.5MG/M2/72HR (3.0 Mg 72hrs Weekly X 6 Wks) (View Topotecan 1.5mg/m2/72hr Review and Topotecan 1.5mg/m2/72hr Label ), LIPITOR (View Lipitor Review and Lipitor Label ), HYDROCHLOROTHIAZIDE (View Hydrochlorothiazide Review and Hydrochlorothiazide Label ), COREG (View Coreg Review and Coreg Label ), MULTI VITAMIN (View Multi-vitamin Review and Multi-vitamin Label ), CALTRATE (View Caltrate Review and Caltrate Label ), DECADRON (View Decadron Review and Decadron Label ), ZANTAC (View Zantac Review and Zantac Label ). Patient was hospitalized.

4611389-2 | Brain Herniation, Brain Oedema, Dyspnoea, Glioblastoma Multiforme, Malignant Neoplasm Progression, Pneumonia, Pneumonia Aspiration
on Mar 15, 2005 Male patient from , weighting 192.5 lb, was diagnosed with glioblastoma multiforme and was treated with Carmustine (View Usage). Patient had the following side effects: brain herniation, brain oedema, dyspnoea, glioblastoma multiforme, malignant neoplasm progression, pneumonia (What is pneumonia?), pneumonia aspiration. Carmustine dosage: 206 Mg Iv Once Q 6 Weeks. During the same period patient was treated with TOPOTECAN 1.5 MG/M2 72 HR (3.1mg Iv Over 72 Hours Weekly X 6 Wks) (View Topotecan 1.5 Mg/m2 72 Hr Review and Topotecan 1.5 Mg/m2 72 Hr Label ), DILANTIN (View Dilantin Review and Dilantin Label ), LEXAPRO (View Lexapro Review and Lexapro Label ), DECADRON (View Decadron Review and Decadron Label ), ZANTAC (View Zantac Review and Zantac Label ), HYDROCODONE BITARTRATE (View Hydrocodone Bitartrate Review and Hydrocodone Bitartrate Label ), PHENERGAN (View Phenergan Review and Phenergan Label ), LEVAQUIN (View Levaquin Review and Levaquin Label ). Patient was hospitalized.

4610986-8 | Pulmonary Embolism
on Mar 15, 2005 Male patient from , weighting 192.5 lb, was diagnosed with glioblastoma multiforme and was treated with Carmustine (View Usage). After Carmustine was administered, patient had the following side effects: pulmonary embolism (What is pulmonary embolism?). Carmustine dosage: 206mg Iv Once Q 6 Weeks. During the same period patient was treated with TOPOTECAN (3.1 Mg Iv Over 72hrs Weekly X 6 Wks) (View Topotecan Review and Topotecan Label ), DILANTIN (View Dilantin Review and Dilantin Label ), LEXAPRO (View Lexapro Review and Lexapro Label ), DECADRON (View Decadron Review and Decadron Label ), PEPCID (View Pepcid Review and Pepcid Label ), PERCOCET (View Percocet Review and Percocet Label ). Patient was hospitalized.

4553743-3 | Bronchitis, Deep Vein Thrombosis, Nasal Congestion, Neutropenia, Pulmonary Embolism, Rhinorrhoea, Sinus Headache
Patient was taking Carmustine (View Usage). Patient experienced the following unwanted or unexpected effects: bronchitis (What is bronchitis?), deep vein thrombosis (What is deep vein thrombosis?), nasal congestion, neutropenia, pulmonary embolism (What is pulmonary embolism?), rhinorrhoea, sinus headache on Jan 14, 2005 from Additional patient health information: Male patient , 49 years of age, weighting 226.0 lb, was diagnosed with astrocytoma and. Carmustine dosage: 510 Mg 1,2,3,56 Intravenous. During the same period patient was treated with DECADRON (14 Mg Day Oral) (View Decadron Review and Decadron Label ), PROTONIX (View Protonix Review and Protonix Label ), LANTUS (View Lantus Review and Lantus Label ), DILANTIN (View Dilantin Review and Dilantin Label ), STOOL SOFTENER (View Stool Softener Review and Stool Softener Label ). Patient was hospitalized.